Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.

导出 LinkOut

翻译打印收藏纠错

作者： Wanheng,Zhang ^[1] ; Kuojun,Zhang ^[1] ; Yiwu,Yao ^[1] ; Yunyao,Liu ^[1] ; Yong,Ni ^[1] ; Chenzhong,Liao ^[2] ; Zhengchao,Tu ^[3] ; Yatao,Qiu ^[1] ; Dexiang,Wang ^[1] ; Dong,Chen ^[1] ; Lei,Qiang ^[1] ; Zheng,Li ^[4] ; Sheng,Jiang ^[5]

作者单位： State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China. ^[1] School of Biological and Medical Engineering, Hefei University of Technology, Hefei, 230009, China. ^[2] Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 10530, China. ^[3] Center for Bioenergetics, Houston Methodist Research Institute, 6670 Bertner, Houston, TX, 77030, United States. Electronic address: zli@houstonmethodist.org. ^[4] State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: jiangsh9@gmail.com. ^[5]

关键词 Antiproliferative activity Antitumor efficacy Dual inhibitor EGFR Multitarget drugs NAMPT